![Jeenjoo Kang](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jeenjoo Kang
Fondatore presso Appia Bio, Inc.
Posizioni attive di Jeenjoo Kang
Società | Posizione | Inizio | Fine |
---|---|---|---|
Appia Bio, Inc.
![]() Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | Direttore/Membro del Consiglio | 01/01/2020 | - |
Amministratore Delegato | 01/01/2020 | - | |
Fondatore | 01/01/2020 | - | |
Escient Pharmaceuticals, Inc.
![]() Escient Pharmaceuticals, Inc. BiotechnologyHealth Technology Escient Pharmaceuticals, Inc. operates as a bio-technology company. It develops in-class G Protein-Coupled Receptor targeted drugs to address serious, unserved medical needs. The company was founded by Alain D. Baron, Marcus F. Boehm and Xinzhong Dong and is headquartered in San Diego, CA. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Jeenjoo Kang
Precedenti posizioni note di Jeenjoo Kang
Società | Posizione | Inizio | Fine |
---|---|---|---|
The Column Group LLC
![]() The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Analista di Private Equity | 01/01/2015 | 01/01/2017 |
Investitore di Private Equity | 01/01/2017 | 31/12/2022 | |
TENAYA THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 01/08/2016 | 17/11/2021 |
Independent Dir/Board Member | 01/08/2016 | 17/11/2021 | |
Exonics Therapeutics, Inc.
![]() Exonics Therapeutics, Inc. BiotechnologyHealth Technology Exonics Therapeutics, Inc. develops therapies for neuromuscular diseases. It also develops gene editing technologies like CRISPR/Cas9 to permanently correct the majority of duchenne muscular dystrophy mutations. The company was founded by Eric N. Olson in February 2017 and is headquartered in Cambridge, MA. | Direttore/Membro del Consiglio | 01/11/2017 | 30/08/2020 |
Formazione di Jeenjoo Kang
Harvard University | Undergraduate Degree |
California Institute of Technology | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 8 |
Posizioni
Director/Board Member | 4 |
Independent Dir/Board Member | 1 |
Private Equity Analyst | 1 |
Settori
Health Technology | 5 |
Consumer Services | 3 |
Finance | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
TENAYA THERAPEUTICS, INC. | Health Technology |
Aziende private | 4 |
---|---|
The Column Group LLC
![]() The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Finance |
Appia Bio, Inc.
![]() Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | Health Technology |
Escient Pharmaceuticals, Inc.
![]() Escient Pharmaceuticals, Inc. BiotechnologyHealth Technology Escient Pharmaceuticals, Inc. operates as a bio-technology company. It develops in-class G Protein-Coupled Receptor targeted drugs to address serious, unserved medical needs. The company was founded by Alain D. Baron, Marcus F. Boehm and Xinzhong Dong and is headquartered in San Diego, CA. | Health Technology |
Exonics Therapeutics, Inc.
![]() Exonics Therapeutics, Inc. BiotechnologyHealth Technology Exonics Therapeutics, Inc. develops therapies for neuromuscular diseases. It also develops gene editing technologies like CRISPR/Cas9 to permanently correct the majority of duchenne muscular dystrophy mutations. The company was founded by Eric N. Olson in February 2017 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Jeenjoo Kang
- Esperienza